Navigation Links
TandemHeart PTVA (Percutaneous Transseptal Ventricular Assist) System

ProductsTandemHeart PTVA (Percutaneous Transseptal Ventricular Assist) System
Company CardiacAssist, Inc.
Item TandemHeart PTVA (Percutaneous Transseptal Ventricular Assist) System
Features Precision molding, machining, and alignment of the VADs' internal parts coupled with the lubrication/anticoagulation system has been shown to curb blood stasis and thrombus formation by providing:
  • A fluid bearing to the impeller/rotor, the only moving part of the VAD, to reduce friction and heat generation
  • Localized anticoagulation to the blood in the interior of the VAD
Description The TandemHeart PTVA (Percutaneous Transseptal Ventricular Assist) System is a unique proprietary solution for the hemodynamic needs of patients for circulatory support by both Cardiologists and Cardiac Surgeons. These specialists have historically used intra-aortic balloon pumps to provide some coronary artery perfusion, but the IABP provides minimal circulatory support. Our vision is to revolutionize the treatment of heart disease by bridging gaps in current technology, and to introduce novel, highly effective therapies for circulatory support.

For the first time, mechanical circulatory support of up to four liters per minute is possible through percutaneous access. The TandemHeart PTVA System gives CardiacAssist a clear and early lead in the circulatory support market for patients in the cath lab. Currently, no other ventricular assist device (VAD) or circulatory support system provides our unique combination of hemodynamic support via a percutaneous approach.

Info CardiacAssist, Inc.
Customer Service: (800) 373-7421
Web site: http://www.cardiacassist.com

Related medicine products :

1. TandemHeart Escort Controller
2. External Ventricular Drainage (EVD)
3. EDM Ventricular Drainage Kit, with Drip Chamber
4. LionHeart Left Ventricular Assist System (LVAS)
5. SVR Surgical Ventricular Restoration System
6. B 3.2 Bipolar Ventricular Lead
7. M 3.2 Unipolar Ventricular Lead
8. Silicone Oil Cannula System - 20 Gauge
9. Silicone Oil Cannula System - 19 Gauge
10. SuperVu Galilean System
11. KOWA nonmyd 7 / VK-2 Digital Imaging System
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products:
(Date:12/3/2008)...e/ -- Consumers for Fair and Affordable,Insurance...hospital systems,including 41 hospitals, are sup...reform. , In a letter to state legislators,...er of Beaumont Hospitals, and several other hospit...ory structure for individual health,insurance is ...
(Date:12/3/2008)...-USNewswire/ -- The American Society of Hematology...mposium at the San Francisco Marriott on Thursday,... symposium, which encourages an interest in hemato...h, is held in conjunction with the Society,s 50th ...opportunity to explore research on sickle cell dis...
(Date:12/3/2008)...llege of Technology has extended its military scho...ve served in Iraq or Afghanistan. This scholarship... is also available to spouses and dependents of mi...Up to $150,000 in scholarships is available for st...logy or Medical Careers Institute, the School of H...
(Date:12/3/2008)...linic study found that patients with low-grade gli...ve surgeries to successfully remove the entire tum...ssible, patients survived significantly longer whe...study is available online as an advance publicatio...journals.org/cgi/content/abstract/15228517-2008-10...
Breaking Medicine News(10 mins):Health News:Over 40 Hospitals Lend Support for Individual Insurance Market Reform 2Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News: ECPI College of Technology and Medical Careers Institute Announce Extension for South Carolina Military Scholarship Opportunity 2Health News:Mayo Clinic identifies best treatments for long-term survival in brain tumor patients 2
...s suffering from problem gambling behavior may sha...sers like drug addicts and alcoholics. Researchers...problem gambling behavior in people and have found...ance abusers. Researchers in their research have p...
...esearch paper on chronic obstructive pulmonary dis...rograms are often useful for patients of this dise...s. Chronic obstructive pulmonary disease (COPD) ar...irflow and conditions like lung tissue destruction...
...id that that it will promote a culture of openness...rt of this vision, FDA will create a new independe...gement of drug safety issues, and will provide eme...and patients about the risks and benefits of medic...
...ssue of the health journal Epidemiology has publis...that the chances of cancer are higher if there is ... the National Cancer Institute, Rockville, Marylan...women treated for infertility between 1965 and 198...
Other Medicine News:Health News:Monitoring Drug Safety 2
(Date:12/1/2008)...Dec. 1 TargeGen has announced that...m a multi-center, US-based clinical,trial of TG10...en scheduled at,the 2008 American Society of Hema...esentation are as follows:, Title: ...lable, JAK2-Selective Inhi...
(Date:12/1/2008)...udy shows the Prox1 gene is a two-way switch that,... to be reprogrammed so that they lose their identi... , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNews...ch Hospital have discovered that a certain differe...ty that it requires the constant expression of a g...
(Date:12/1/2008)...ce Call Scheduled for Tuesday, December 9 at 11:00... , , SOUTH SAN FRANCISCO, Calif., Dec. 1 ... Inc. (Nasdaq: SNSS ), a biopharmaceutical compa...n of new oncology therapeutics, today announced ne...oid leukemia (AML) will be presented during the 50...
(Date:11/30/2008)...c. 1 Abnormalities in a...n children with autism spectrum disorder by using ... presented today at the annual meeting of the Radi... "Using MEG, we can record the tiny magnetic fie...id Timothy Roberts, Ph.D., vice chair of research ...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals Inc and Announces Subsequent Offering Period 5252 1Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals Inc and Announces Subsequent Offering Period 5252 2Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals Inc and Announces Subsequent Offering Period 5252 3Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals Inc and Announces Subsequent Offering Period 5252 4Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals Inc and Announces Subsequent Offering Period 5252 5New Study Demonstrates ACTEMRA 28R 29 28tocilizumab 29 Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2021 1New Study Demonstrates ACTEMRA 28R 29 28tocilizumab 29 Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2021 2New Study Demonstrates ACTEMRA 28R 29 28tocilizumab 29 Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2021 3New Study Demonstrates ACTEMRA 28R 29 28tocilizumab 29 Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2021 4New Study Demonstrates ACTEMRA 28R 29 28tocilizumab 29 Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2021 5Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008 18879 1Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008 18879 2Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008 18879 3Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 18878 1Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 18878 2Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 18878 3Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 18878 4Strike Force Targets Medicare Fraud By Los Angeles Area Health Care Companies 18878 5
...y 23, 2007 /PRNewswire-FirstCall/,-- Napo Pharmace...and commercialization of proprietary pharmaceutica...h local partners, announced that,Trine Pharmaceuti...ing the results of a Phase 2a study conducted in 2...able bowel syndrome,(d-IBS) today at Digestive Dis...
...ized with Genous Stent, BARCELONA, Spain, May 23, ...Genous(TM) Bio-engineered R stent compares favorab...of late thrombosis,is minimized with the Genous st...eting data presented today by Robbert de,Winter, M... Collected from more than 120 sites in 29 countrie...
Other Medicine Technology:Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C. 2Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C. 3Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C. 4Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from,2006 Presented at Digestive Disease Week in Washington, D.C. 5Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3